ALTERITY THERAPEUTICS LTD (ATHE) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ATHE currently has 5.25B outstanding shares. with minimal authorized share overhang for future dilution. The company has not diluted shareholders through share issuances in the past 2 years, which is positive for existing holders.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Sep 26, 2024 |
20-F filing | 5245.1M shares outstanding |
5.2B | 0 |
| Oct 02, 2023 |
F-3 filing: The filing is an F-3 registration statement for Alterity Therapeutics Limited relating to the potential offering of American depositary shares, or ADSs, warrants to purchase ADSs, or a combination of the above as units, with a total public offering price not to exceed $50,000,000. |
2.4B | 0 |
| Aug 31, 2023 |
20-F filing | 2439.9M shares outstanding |
2.4B | 0 |
| Aug 31, 2022 |
20-F filing | 2406.9M shares outstanding |
2.4B | 0 |
| Sep 02, 2021 |
20-F filing | 2084.0M shares outstanding |
2.1B | 0 |
| Dec 23, 2020 |
F-3 filing: This is an F-3 filing related to a statement of expenses in connection with the distribution of registered securities, with estimated expenses not including offerings of particular securities. |
1B | 25M |
| Nov 13, 2020 |
F-3 filing: This is a statement of expenses in connection with the distribution of the securities registered. All amounts shown are estimates except the SEC registration fee. |
1B | 25M |
| Oct 05, 2020 |
F-3 filing: The company may offer American depositary shares, warrants, or a combination of both, with a total public offering price not to exceed $50,000,000. |
1B | 25M |
| Sep 15, 2020 |
20-F filing | 1037.4M shares outstanding |
1B | 0 |